SARS ‐ CoV ‐2: A Liver Brief
WIREs Mechanisms of Disease · 2025
DOI: 10.1002/wsbm.70005 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift WIREs Mechanisms of Disease, 2025. Verfasst von Youness Limami und 9 weiteren Autor:innen. Beteiligte Einrichtung: Sciences and Engineering of Biomedicals, Biophysics and Health Laboratory, Higher Institute of Health Sciences, Hassan First University, Settat, Moro…. Hauptthemen laut MEDLINE: COVID-19, SARS-CoV-2, Liver Diseases, Liver. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 235 Literaturangaben.
Abstract (Originalsprache)
The Coronavirus Disease 2019 (COVID‐19) pandemic, caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‐CoV‐2), has revealed the virus's ability to induce multi‐organ damage, including significant liver injury. The molecular mechanisms of liver dysfunction in COVID‐19 patients are explored, focusing on direct viral infection, immune‐mediated damage, and the gut–liver axis. SARS‐CoV‐2 enters liver cells through the Angiotensin‐Converting Enzyme 2 (ACE2) and Transmembrane Serine Protease 2 (TMPRSS2) receptors, but alternative pathways, such as CD209/Dendritic Cell‐Specific Intercellular adhesion molecule‐3‐Grabbing Non‐integrin (DC‐SIGN) and AXL receptors, can also contribute to viral entry. Additionally, immune responses, particularly the cytokine storm, exacerbate liver inflammation, leading to hepatocyte damage. Pre‐existing liver conditions, such as metabolic‐associated fatty liver disease (MAFLD), alcohol‐related liver disease (ALD), and liver fibrosis, heighten the risk of severe outcomes in COVID‐19 patients. Post‐COVID‐19 liver complications, including fibrosis progression and persistent liver damage, have been reported, with emerging evidence suggesting chronic inflammation, viral persistence, and autoimmune reactions as potential contributors. Furthermore, Drug‐Induced Liver Injury (DILI) from COVID‐19 treatments remains a concern, highlighting the need for careful management. Consequently, understanding the interplay between SARS‐CoV‐2 and the liver is critical for improving patient outcomes and developing targeted therapies to mitigate liver‐related complications in both acute and Long COVID‐19 phases. This article is categorized under: Infectious Diseases > Molecular and Cellular Physiology
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Sciences and Engineering of Biomedicals, Biophysics and Health Laboratory, Higher Institute of Health Sciences, Hassan First University, Settat, Morocco.
- Laboratory of Immunology and Biodiversity, Faculty of Sciences Ain Chock, Hassan II University, Casablanca, Morocco.
- Université de Lorraine, Nancy, France.
ORCID-Profile: Youness Limami, Hicham Wahnou, Martin Ndayambaje, Soufyane Hba, Oumaima Chgari, Mounia Ammara, Riad El Kebbaj, Abdallah Naya, Mounia Oudghiri, Raphaël Emmanuel Duval
Zitieren
APA
Limami, Y., Wahnou, H., Ndayambaje, M., Hba, S., Chgari, O., Ammara, M., El Kebbaj, R., Naya, A., Oudghiri, M., & Duval, R. E. (2025). SARS ‐ CoV ‐2: A Liver Brief. WIREs Mechanisms of Disease. https://doi.org/10.1002/wsbm.70005
Vancouver
Limami Y, Wahnou H, Ndayambaje M, Hba S, Chgari O, Ammara M, et al. SARS ‐ CoV ‐2: A Liver Brief. WIREs Mechanisms of Disease. 2025. doi:10.1002/wsbm.70005
BibTeX
@article{Limami2025,
author = {Limami, Youness and Wahnou, Hicham and Ndayambaje, Martin and Hba, Soufyane and Chgari, Oumaima and Ammara, Mounia and El Kebbaj, Riad and Naya, Abdallah and Oudghiri, Mounia and Duval, Raphaël Emmanuel},
title = {SARS ‐ CoV ‐2: A Liver Brief},
journal = {WIREs Mechanisms of Disease},
year = {2025},
doi = {10.1002/wsbm.70005}
}
EUVIMED